GB0319690D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0319690D0
GB0319690D0 GBGB0319690.4A GB0319690A GB0319690D0 GB 0319690 D0 GB0319690 D0 GB 0319690D0 GB 0319690 A GB0319690 A GB 0319690A GB 0319690 D0 GB0319690 D0 GB 0319690D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0319690.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0319690.4A priority Critical patent/GB0319690D0/en
Publication of GB0319690D0 publication Critical patent/GB0319690D0/en
Priority to JP2006524409A priority patent/JP2007503421A/ja
Priority to US10/567,798 priority patent/US20060199966A1/en
Priority to EP04801875A priority patent/EP1660448A1/en
Priority to PCT/GB2004/003552 priority patent/WO2005019172A1/en
Priority to UY28485A priority patent/UY28485A1/es
Priority to TW093125214A priority patent/TW200510304A/zh
Priority to ARP040103021A priority patent/AR045477A1/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0319690.4A 2003-08-22 2003-08-22 Chemical compounds Ceased GB0319690D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0319690.4A GB0319690D0 (en) 2003-08-22 2003-08-22 Chemical compounds
JP2006524409A JP2007503421A (ja) 2003-08-22 2004-08-18 化学化合物
US10/567,798 US20060199966A1 (en) 2003-08-22 2004-08-18 Indol-2-amides as glycogen phosphorylase inhibitors
EP04801875A EP1660448A1 (en) 2003-08-22 2004-08-18 Indol-2-amides as glycogen phosphorylase inhibitors
PCT/GB2004/003552 WO2005019172A1 (en) 2003-08-22 2004-08-18 Indol-2-amides as glycogen phosphorylase inhibitors
UY28485A UY28485A1 (es) 2003-08-22 2004-08-20 Compuestos quimicos
TW093125214A TW200510304A (en) 2003-08-22 2004-08-20 Chemical compounds
ARP040103021A AR045477A1 (es) 2003-08-22 2004-08-23 Amidas heterociclicas como inhidores de la glucogeno fosforilasa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0319690.4A GB0319690D0 (en) 2003-08-22 2003-08-22 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0319690D0 true GB0319690D0 (en) 2003-09-24

Family

ID=28460083

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0319690.4A Ceased GB0319690D0 (en) 2003-08-22 2003-08-22 Chemical compounds

Country Status (8)

Country Link
US (1) US20060199966A1 (enExample)
EP (1) EP1660448A1 (enExample)
JP (1) JP2007503421A (enExample)
AR (1) AR045477A1 (enExample)
GB (1) GB0319690D0 (enExample)
TW (1) TW200510304A (enExample)
UY (1) UY28485A1 (enExample)
WO (1) WO2005019172A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US20040082641A1 (en) * 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7098235B2 (en) * 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
BRPI0409952A (pt) * 2003-04-30 2006-04-25 Pfizer Prod Inc agentes anti-diabéticos

Also Published As

Publication number Publication date
WO2005019172A1 (en) 2005-03-03
TW200510304A (en) 2005-03-16
US20060199966A1 (en) 2006-09-07
UY28485A1 (es) 2005-03-31
AR045477A1 (es) 2005-10-26
EP1660448A1 (en) 2006-05-31
JP2007503421A (ja) 2007-02-22

Similar Documents

Publication Publication Date Title
GB0317009D0 (en) Chemical compounds
GB0308208D0 (en) Chemical compounds
GB0319124D0 (en) Chemical compounds
GB0311276D0 (en) Chemical compounds
GB0315203D0 (en) Chemical compounds
GB0311274D0 (en) Chemical compounds
EP1590339A4 (en) CHEMICAL COMPOUNDS
GB0319759D0 (en) Chemical compounds
GB0318422D0 (en) Chemical compounds
GB0318423D0 (en) Chemical compounds
EP1654251A4 (en) CHEMICAL COMPOUNDS
GB0308801D0 (en) Chemical compounds
GB0319690D0 (en) Chemical compounds
GB0306358D0 (en) Chemical compounds
GB0310724D0 (en) Chemical compounds
GB0306357D0 (en) Chemical compounds
GB0314373D0 (en) Chemical compounds
GB0304723D0 (en) Chemical compounds
GB0310464D0 (en) Chemical compounds
GB0314370D0 (en) Chemical compounds
GB0315872D0 (en) Chemical compounds
GB0319149D0 (en) Chemical compounds
GB0307632D0 (en) Chemical compounds
GB0307633D0 (en) Chemical compounds
GB0312775D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)